Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status

Pharmacological Reports

Volumn 68, Issue 6, 2016, Pages 1266-1275

  Jaroch, Karol ^a   Karolak, Maciej ^a   Górski, Przemysław ^a   Jaroch, Alina ^a   Krajewski, Adrian ^a   Ilnicka, Aleksandra ^b   Sloderbach, Anna ^a   Stefański, Tomasz ^c,d   Sobiak, Stanisław ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

CA4P; Clinical trials; Combretastatin; SAR; Structure activity relationship

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; COMBRETASTATIN; COMBRETASTATIN A4 PHOSPHATE; ANGIOGENESIS INHIBITOR; STILBENE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; CANCER CELL; CANCER PAIN; CARDIOTOXICITY; CELL DEATH; CLINICAL TRIAL (TOPIC); COMBRETUM; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; IN VITRO STUDY; ISOMERIZATION; NEUROTOXICITY; QT PROLONGATION; QTC INTERVAL; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; NAUSEA; NEOPLASM; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; HUMANS; NAUSEA; NEOPLASMS; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84988688657     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2016.08.007     Document Type: Review

References (60)

1. [1] Bauer-Kosińska, B., Contemporary systemic preoperative treatment of breast cancer – hormonotherap. Onkol Prakt Klin 4 (2008), 57–61 (Polish).
2. [2] Sobańska, K., Szałek, E., Kamińska, A., Grześkowiak, E., Tyrosine kinase inhbitors in anticancer therapy. Farm Współ 4 (2011), 185–190 (Polish).
3. [3] Nishida, N., Yano, H., Nishida, T., Kamura, T., Kojiro, M., Angiogenesis in cancer. Vasc Health Risk Manage 2:3 (2006), 213–219.
4. [4] Gaya, A.M., Rustin, G.J.S., Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 17:4 (2005), 277–290.
5. [5] Kanthou, C., Greco, O., Stratford, A., Cook, I., Knight, R., Benzakour, O., et al. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol 165:4 (2004), 1401–1411.
6. [6] Pettit, G.R., Singh, S.B., Niven, M.L., Hamel, E., Schmidt, J.M., Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50:1 (1987), 119–131.
7. [7] Pettit, G.R., Temple, C., Narayanan, V.L., Varma, R., Simpson, M.J., Boyd, M.R., et al. Antineoplastic agents 322: synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:4 (1995), 299–309.
8. [8] Dark, G.G., Hill, S.A., Prise, V.E., Tozer, G.M., Pettit, G.R., Chaplin, D.J., Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:10 (1997), 1829–1834.
9. [9] Cushman, M., Nagarathnam, D., Gopal, D., Chakraborti, A.K., Lin, C.M., Hamel, E., Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem 34:8 (1991), 2579–2588.
10. [10] Simoni, D., Grisolia, G., Giannini, G., Roberti, M., Rondanin, R., Piccagli, L., et al. Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J Med Chem 48:3 (2005), 723–736.
11. [11] Kumar, S., Mehndiratta, S., Nepali, K., Gupta, M.K., Koul, S., Sharma, P.R., et al. Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors. Org Med Chem Lett, 3(1), 2013, 3.
12. [12] O'Boyle, N.M., Greene, L.M., Keely, N.O., Wang, S., Cotter, T.S., Zisterer, D.M., et al. Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting '-lactam combretastatins. Eur J Med Chem 62 (2013), 705–721.
13. [13] Lee, M., Brockway, O., Dandavati, A., Tzou, S., Sjoholm, R., Satam, V., et al. A novel class of trans-methylpyrazoline analogs of combretastatins: synthesis and in-vitro biological testing. Eur J Med Chem 46:7 (2011), 3099–3104.
14. [14] LeBlanc, R., Dickson, J., Brown, T., Stewart, M., Pati, H.N., VanDerveer, D., et al. Synthesis and cytotoxicity of epoxide and pyrazole analogs of the combretastatins. Bioorg Med Chem 13:21 (2005), 6025–6034.
15. [15] Johnson, M., Younglove, B., Lee, L., LeBlanc, R., Holt, H., Hills, P., et al. Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. Bioorg Med Chem Lett 17:21 (2007), 5897–5901.
16. [16] Ruprich, J., Prout, A., Dickson, J., Younglove, B., Nolan, L., Baxi, K., et al. Design, synthesis and biological testing of cyclohexenone derivatives of combretastatin-A4. Lett Drug Des Discov 4:2 (2007), 144–148.
17. [17] Lee, L., Robb, L., Lee, M., Davis, R., Mackay, H., Chavda, S., et al. Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4. J Med Chem 53:1 (2010), 325–334.
18. [18] Yeo, W., Loong, H., Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. Onco Targets Ther 7 (2014), 575–585.
19. [19] Sacewicz, I., Wiktorska, M., Wysocki, T., Niewiarowska, J., Mechanisms of cancer angiogenesis. Postepy Hig Med Dosw 63 (2009), 159–168 (Polish Online).
20. [20] Schwartz, E.L., Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:8 (2009), 2594–2601.
21. [21] Siemann, D.W., Chaplin, D.J., Walicke, P.A., A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Invest Drugs 18:2 (2009), 189–197.
22. [22] Chaplin, D.J., Horsman, M.R., The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiother Oncol 30:1 (1994), 59–65.
23. [23] Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S.A.A., Fack, F., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 108:9 (2011), 3749–3754.
24. [24] Doñate, Antiangiogenic therapy in cancer. Drugs Future, 2005, 695.
25. [25] Galbraith, S.M., Chaplin, D.J., Lee, F., Stratford, M.R., Locke, R.J., Vojnovic, B., et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21:1A (2001), 93–102.
26. [26] Griggs, J., Hesketh, R., Smith, G.A., Brindle, K.M., Metcalfe, J.C., Thomas, G.A., et al. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br J Cancer 84:6 (2001), 832–835.
27. [27] Chaplin, D.J., Dougherty, G.J., Tumour vasculature as a target for cancer therapy. Br J Cancer 1999:Suppl. 1 (1999), 57–64.
28. [28] Tozer, G.M., Prise, V.E., Wilson, J., Locke, R.J., Vojnovic, B., Stratford, M.R., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59:7 (1999), 1626–1634.
29. [29] Stepień, A., Izdebska, M., Grzanka, A., The types of cell death. Postepy Hig Med Dosw 61 (2007), 420–428 (Polish Online).
30. [30] Vitale, I., Antoccia, A., Cenciarelli, C., Crateri, P., Meschini, S., Arancia, G., et al. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis 12:1 (2007), 155–166.
31. [31] Lin, H.-L.L., Chiou, S.-H.H., Wu, C.-W.W., Lin, W.-B.B., Chen, L.-H.H., Yang, Y.-P.P., et al. Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells. J Pharmacol Exp Ther 323:1 (2007), 365–373.
32. [32] Petit, I., Karajannis, M.A., Vincent, L., Young, L., Butler, J., Hooper, A.T., et al. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 111:4 (2008), 1951–1961.
33. [33] Shen, C.-H.H., Shee, J.-J.J., Wu, J.-Y.Y., Lin, Y.-W.W., Wu, J.-D.D., Liu, Y.-W.W., Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol 160:8 (2010), 2008–2027.
34. [34] Nabha, S.M., Mohammad, R.M., Dandashi, M.H., Coupaye-Gerard, B., Aboukameel, A., Pettit, G.R., et al. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 8:8 (2002), 2735–2741.
35. [35] Mikstacka, R., Stefański, T., Różański, J., Tubulin-interactive stilbene derivatives as anticancer agents. Cell Mol Biol Lett 18:3 (2013), 368–397.
36. [36] Tron, G.C., Pirali, T., Sorba, G., Pagliai, F., Busacca, S., Genazzani, A.A., Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 49:11 (2006), 3033–3044.
37. [37] Ma, M., Sun, L., Lou, H., Ji, M., Synthesis and biological evaluation of Combretastatin A-4 derivatives containing a 3′-O-substituted carbonic ether moiety as potential antitumor agents. Chem Cent J, 7(1), 2013, 179.
38. [38] Pettit, G.R., Minardi, M.D., Rosenberg, H.J., Hamel, E., Bibby, M.C., Martin, S.W., et al. Antineoplastic agents: 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1). J Nat Prod 68:10 (2005), 1450–1458.
39. [39] Fortin, S., Moreau, E., Lacroix, J., Teulade, J.C.C., Patenaude, A., C-Gaudreault, R., N-Phenyl-N’-(2-chloroethyl)urea analogues of combretastatin A-4: is the N-phenyl-N’-(2-chloroethyl)urea pharmacophore mimicking the trimethoxy phenyl moiety?. Bioorg Med Chem Lett 17:7 (2007), 2000–2004.
40. [40] Simoni, D., Romagnoli, R., Baruchello, R., Rondanin, R., Grisolia, G., Eleopra, M., et al. Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity. J Med Chem 51:19 (2008), 6211–6215.
41. [41] Dzierzbicka, K., Kubacka, P., Renusz, S., Kołodziejczyk, A., Combretastatin, A.-4, (CA-4) and its analogues: synthesis and biological activity. Polish) Wiad Chem 62 (2008), 1037–1064.
42. [42] Chaudhary, A., Pandeya, Kumar, Sharma, Gupta, Soni, et al. Combretastatin A-4 analogs as anticancer agents. Mini Rev Med Chem 7:12 (2007), 1186–1205.
43. [43] Anderson, H., Yap, J., Miller, M., Robbins, A., Jones, T., Price, P., Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21:15 (2003), 2823–2830.
44. [44] Stevenson, J.P., Rosen, M., Sun, W., Gallagher, M., Haller, D., Vaughn, D., et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:23 (2003), 4428–4438.
45. [45] Bilenker, J., Flaherty, K., Rosen, M., Davis, L., Gallagher, M., Stevenson, J., et al. Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 11:4 (2005), 1527–1533.
46. [46] Dowlati, A., Robertson, K., Cooney, M., Petros, W.P., Stratford, M., Jesberger, J., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:12 (2002), 3408–3416.
47. [47] Nathan, P., Zweifel, M., Padhani, A.R., Koh, D.-M.M., Ng, M., Collins, D.J., et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 18:12 (2012), 3428–3439.
48. [48] He, X., Li, S., Huang, H., Li, Z., Chen, L., Ye, S., et al. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. Br J Clin Pharmacol 71:6 (2011), 860–870.
49. [49] Zweifel, M., Jayson, G.C., Reed, N.S., Osborne, R., Hassan, B., Ledermann, J., et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22:9 (2011), 2036–2041.
50. [50] Meyer, T., Gaya, A.M., Dancey, G., Stratford, M.R., Othman, S., Sharma, S.K., et al. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res 15:13 (2009), 4484–4492.
51. [51] Ng, Q.S., Mandeville, H., Goh, V., Alonzi, R., Milner, J., Carnell, D., et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 23:1 (2012), 231–237.
52. [52] Rustin, G.J., Galbraith, S.M., Anderson, H., Stratford, M., Folkes, L.K., Sena, L., et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:15 (2003), 2815–2822.
53. [53] Rustin, G.J., Shreeves, G., Nathan, P.D., Gaya, A., Ganesan, T.S., Wang, D., et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 102:9 (2010), 1355–1360.
54. [54] Patterson, D.M., Zweifel, M., Middleton, M.R., Price, P.M., Folkes, L.K., Stratford, M.R., et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 18:5 (2012), 1415–1425.
55. [55] Ibrahim, M.A., Do, D.V., Sepah, Y.J., Shah, S.M., Van, Anden E., Hafiz, G., et al. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol, 14, 2013, 7.
56. [56] Cooney, M., Radivoyevitch, T., Dowlati, A., Overmoyer, B., Levitan, N., Robertson, K., et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-Dose phase I study in patients with advanced cancer. Clin Cancer Res 10 (2004), 96–100.
57. [57] Liu, P., Qin, Y., Wu, L., Yang, S., Li, N., Wang, H., et al. A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections. Anticancer Drugs 25:4 (2014), 462–471.
58. [58] Combes, S., Barbier, P., Douillard, S., McLeer-Florin, A., Bourgarel-Rey, V., Pierson, J.-T.T., et al. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins Part 2. J Med Chem 54:9 (2011), 3153–3162.
59. [59] Galli, U., Travelli, C., Aprile, S., Arrigoni, E., Torretta, S., Grosa, G., et al. Design, synthesis, and biological evaluation of combretabenzodiazepines: a novel class of anti-tubulin agents. J Med Chem 58:3 (2015), 1345–1357.
60. [60] Zhou, J., Jin, J., Zhang, Y., Yin, Y., Chen, X., Xu, B., Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4. Eur J Med Chem 68 (2013), 222–232.